Evolent Health, Inc. (EVH)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

34.62

-0.74

(-2.11%)

As of 10:05AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	35.36
Open	35.35
Bid	34.80 x 800
Ask	35.02 x 1100
Day's Range	34.50 - 35.22
52 Week Range	21.36 - 39.00
Volume	110,539
Avg. Volume	895,859

Market Cap	3.173B
Beta (5Y Monthly)	1.86
PE Ratio (TTM)	N/A
EPS (TTM)	-0.38
Earnings Date	Nov 01, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	46.14

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EVH

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Evolent Health, Inc
Weekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.
Rating
Fair Value
Economic Moat
8 days agoArgus Research